References
- Murray AK, Moore TL, Manning JB, Taylor C, Griffiths CEM, Herrick AL. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum 2009;61:1103–11.
- Sandqvist G, Hesselstrand R, Eberhardt K. A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis. Scand J Rheumatol 2009;18:1–7.
- Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002;9:2410–20.
- Georeges C, Chassany O, Mouthon L, Tiev K, Toledano C, Meyer O, et al. Validation of French version of the scleroderma health assessment questionnaire (SSc HAQ). Clin Rheumatol 2005;24:3–10.
- Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
- Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. Criteria 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747–55.
- Medsger TA Jr, Steen VD. Classification, prognosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins, 1996:51–64.
- WHO. International Classification of Functioning, Disability and Health (http://www.who.int/classifications/icf/en/). Accessed 10 July 2017.
- Pauling JD, Shipley JA, Hart DJ, McGrogan A, McHugh NJ. Use of laser speckle contrast imaging to assess digital microvascular function in primary Raynaud phenomenon and systemic sclerosis: a comparison using the Raynaud condition score diary. J Rheumatol 2015;42:1163–8.